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ABSTRACT
Human multiple myeloma (MM) is characterized by accumulation of malignant 
terminally differentiated plasma cells (PCs) in the bone marrow (BM), raising the 
question when during maturation neoplastic transformation begins. Immunoglobulin 
IGHV genes carry imprints of clonal tumor history, delineating somatic hypermutation 
(SHM) events that generally occur in the germinal center (GC). Here, we examine 
MM-derived IGHV genes using massive parallel deep sequencing, comparing them 
with profiles in normal BM PCs. In 4/4 presentation IgG MM, monoclonal tumor-
derived IGHV sequences revealed significant evidence for intraclonal variation (ICV) 
in mutation patterns. IGHV sequences of 2/2 normal PC IgG populations revealed 
dominant oligoclonal expansions, each expansion also displaying mutational ICV. 
Clonal expansions in MM and in normal BM PCs reveal common IGHV features. In 
such MM, the data fit a model of tumor origins in which neoplastic transformation 
is initiated in a GC B-cell committed to terminal differentiation but still targeted by  
on-going SHM. Strikingly, the data parallel IGHV clonal sequences in some monoclonal 
gammopathy of undetermined significance (MGUS) known to display on-going SHM 
imprints. Since MGUS generally precedes MM, these data suggest origins of MGUS and 
MM with IGHV gene mutational ICV from the same GC B-cell, arising via a distinctive 
pathway.
INTRODUCTION
In multiple myeloma (MM), malignant plasma cells 
accrue in the bone marrow (BM) expressing CD138, a 
marker of terminal B-cell differentiation. In MM, an early 
question has been the nature of the cell of origin or normal 
B-cell counterpart in which neoplastic transformation 
begins. Addressing this question, immunoglobulin 
variable gene (IGV) analyses in MM have provided pivotal 
insights.
IGV genes encode the antigen-binding domain of the 
immunoglobulin molecules in the B-cell receptor (BCR), 
a receptor that is essential to survival and maturation of 
normal B-cells [1]. Pathways of B-cell maturation are 
determined by the context in which antigen is seen via the 
BCR. In the presence of cognate T-cell help, a distinctive 
phase of differentiation is initiated in the germinal center 
(GC), in secondary follicles of lymphoid organs that leads 
to the mainstay of memory, generating memory B-cells or 
long-lived plasma cells (LLPCs) located in the BM [2, 3]. 
The GC can be morphologically compartmentalized to 
two areas, a dark zone (DZ) of proliferating B-cells or 
centroblasts (CBs) that downmodulate BCR and express 
CXCR4, and the light zone (LZ) of small B-cells or 
centrocytes (CCs) expressing BCR and CXCR5 [4]. 
Affinity maturation to improve BCR fit for antigen occurs 
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by targeted somatic hypermutation (SHM) of IGV genes, 
initiated by activation induced cytidine deaminase (AID) 
that is expressed at high levels in CBs in the DZ [2–6]. 
Following proliferation, selection of B-cells by antigen 
occurs after migration to the LZ in CCs, and is dependent 
on affinity for antigen complexes presented by follicular 
dendritic cells and interaction with follicular TH (TFH) 
cells [7]. Precise imaging experiments have shown that 
CBs and CCs shunt bi-directionally between the DZ and 
LZ [8], to permit continued induction of SHM. Isotype 
class switch recombination (CSR) also occurs in the GC, 
and can be initiated in cells on the cusp of proliferating 
clonally [9]. CSR is an irrevocable process of deletional 
DNA recombination events dependent on AID activity 
[6]. B-cells selected by antigen exit the GC to two fates, 
circulating as CD27+ human memory B-cells or as cells 
committed to LLPC maturation that home and reside in 
the BM [3–5, 10, 11].
IGV gene analysis in B-cell neoplasms can 
delineate transit via the GC, and the precise pattern 
of SHM in clonally-related transcripts provides clear 
insight into when neoplastic transformation is likely to 
have occurred [12]. In MM, early data from heavy chain 
IGHV gene analyses from our group and others revealed 
an extensive SHM load in tumor-derived sequences, and 
sequencing of tumor transcripts segregated by standard 
cloning strategies and Sanger sequencing revealed 
intraclonally homogeneous IGHV sequences, consistent 
with transformation occurring at a post-follicular stage 
with SHM silenced [12]. However, when we examined 
IGHV gene sequences in monoclonal gammopathy of 
undetermined significance (MGUS), we observed that 
tumor-derived IGHV sequences revealed a marked 
intraclonal variation (ICV) in mutation patterns in some 
cases, implicating neoplastic arrest in MGUS with ICV at 
an earlier stage of maturation, at a stage consistent with 
exposure of the cell of origin to on-going SHM in the 
GC [13]. Furthermore, when we examined progression 
of MGUS-MM in paired cases by IGHV analysis, we 
observed that in one MGUS-MM pair, we could locate 
variant MGUS-like IGHV mutations also in MM clonal 
sequences [14]. At that point in our studies, we suggested 
that MM evolves by cloning out of MGUS-like cells [14]. 
Given the technical limitations of cloning and sequencing 
strategies used earlier in the analysis of the MM clone by 
IGHV analysis, and our initial observations that clonal 
variants could persist in MM from an MGUS stage, we 
reasoned that if the IGHV sequencing depth is ramped 
up, as currently feasible by next generation sequencing, 
it may be possible to observe ICV more commonly in 
MM, with new implications for tumor origins. To do this, 
we have carried out massive deep parallel sequencing 
of IGHV genes in 4 of 4 symptomatic IgG MM cases 
at presentation, comparing findings with 2 of 2 cases of 
normal PCs purified from BM and 1 control IgA MM 
case in which non-tumor IgG transcripts were amplified. 
Our data substantiate our hypothesis, and we find clear 
evidence for ICV among clonal MM-derived IGHV 
sequences. This suggests as the most likely model that 
MM can originate in a GC B-cell committed to terminal 
maturation but still targeted by SHM.
RESULTS
Deep sequencing IGHV gene IgG transcripts and 
error rate
IGHV gene IgG transcripts from malignant and 
normal BM PCs were analyzed by next-generation deep 
sequencing. Following read-pair alignment and sequence 
quality filtering, the total number of high quality reads 
for both technical replicates in each donor ranged from 
97,698 to 2,009,338. The percentage of reads for each 
unique IGHV sequence was congruent between the two 
technical replicates (Figure S1). To increase confidence 
that reads represented true sequence variants rather than 
errors introduced by base mis-incorporation during PCR 
or sequencing mis-reads, sequence variants were only 
analyzed where they were present at high frequency in 
both technical replicates. No clonotype sequences with 
high read counts were exclusive to a single technical 
replicate.
IGHV gene use in MM
Single tumor-derived clonal IGHV sequences 
were readily identified in 4 of 4 MM cases with identical 
CDR3 nucleotide motifs to establish monoclonality, and 
utilized germline genes IGHV2-70D*04, IGHV3-30*18, 
IGHV4-39*01, and IGHV4-59*01 respectively, each 
displaying marked imprint of SHM with % homology to 
germline varying between 89.3 – 94.6 (Figure 1). In these 
samples, the same CDR3 sequence was found in between 
74.0 – 87.3% of reads, surpassing cut-offs of >5% used 
to identify clonal IGHV gene use by deep sequencing 
[15]. Total reads from 2 replicates with identical CDR3 
in respective cases were: MM1 (1,660,375); MM2 
(1,232,656); MM3 (1,218,020); and MM4 (2,009,338) 
(Table S1). No dominant clonal IgG sequence was 
identifiable in control MM5 case, as expected.
Pattern of SHM in MM-derived IGHV gene 
sequences
Analysis of all reads sharing clonal CDR3 motifs 
revealed subclonal variant sequence expansions in 
monoclonal IGHV gene tumor-derived sequences in MM1-4. 
Multiple variant sub-clonal sequence expansions were 
identified. Of these, the top 10 subclonal variant sequences 
are shown, each aligned to the dominant sequence at 
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the nucleotide level, with the top read shown aligned to 
germline (Figure 1). The number of sequences identified 
in the top 10 tumor-derived subclonal expansions differed: 
MM1 (790–2,862 sequences); MM2 (2,574–608,012 
sequences); MM3 (2825–571,958 sequences); and MM4 
(2129–1,393,460 sequences) (Figure 1).
Tumor-derived subclonal sequences as shown were 
identical, e.g. in MM1 the dominant subclonal sequence 
Figure 1: Marked intraclonal variation in tumor-derived IGHV gene sequences in MM. The pool of IgG transcripts 
identified from deep sequencing were aligned by computational analysis with donor germline IGHV genes and CDR3 identity used to 
delineate tumor-derived clonal sequences. Only selected informative codons are shown, focusing on revealing replacement nucleotides that 
arise by SHM for purposes of clarity. The % homology to germline IGHV gene of dominant clonal sequence in MM1-4 is stated in each 
case, and the dominant sequence is shown aligned to the germline gene. Data on the top 10 clonally-derived MM tumor IGHV sequences 
are shown aligned to the dominant sequence or top read, and not the germline gene to reveal the significant intraclonal variation observed 
in mutation patterns (dots denote sequence identity to the top read). For MM1 and MM2 aligned sequence matches start at position 43, for 
MM3 at position 65, and for MM4 at position 68. Translation to deduced amino acid (aa) sequences are shown aligning germline aa with 
replacement aa resulting from mutations in tumor IGHV gene sequences (denoted with *, and no change as -). No dominant clonal IGHV 
gene sequence was identified in the control MM5.
Oncotarget4www.impactjournals.com/oncotarget
gave a count of 2862 and these were all homogeneous in 
sequence (Figure 1). In MM1, the dominant subclonal 
homogeneous sequence and the second-most prevailing 
variant sequence were comparable in number. In 3 of 
4 MM cases (MM2-4), the dominant subclonal sequence 
far surpassed in number the second-most predominant 
variant sequence. These data indicate that the level of ICV 
differed between the 4 MM cases and that in cases MM2-4 
the tumor clones are dominated by a homogeneous clonal 
outgrowth.
Nevertheless, the proportion of variant sub-clonal 
sequence reads over and above the dominant sequence 
or top read were substantial and were found to comprise 
99.8% in MM1, 50.7% in MM2, 53.0% in MM3 and in 
MM4 30.7% of the entire tumor clone (calculated from 
reads in Table S1).
Strikingly, in each of the 4 MM cases, there is 
extensive evidence of ICV as revealed by multiple variant 
IGHV sequences derived from a single tumor clone 
(Figure 1). These data derive from 4 ‘biological replicates’ 
(MM1-4) in experimental terms and yield reproducible 
results.
Profile of non-tumor PCs in MM samples
IgG transcript profiles in MM1-4 indicated that 
profiles of non-tumor IgG PCs were markedly depressed 
(Figure 2).
IGHV gene use in normal PCs
A diverse repertoire of IGHV gene use was observed 
in IgG transcripts in normal PCs in samples NPC1-2; 
however, most of these were expressed at low frequencies 
(data not shown). IgG transcripts were grouped by IGHV 
gene germline use and expression levels mapped on 
a linear scale based on % frequencies (Figure 2). The 
overall use of IGHV2-5 germline gene was the largest and 
common to NPC1-2 and MM5, followed by frequency of 
usage of the IGHV1-69 gene in these 3 samples (Figure 2). 
In the control IgA MM5 case, usage of germline IGHV 
gene elements resembled that seen in NPC1-2 (Figure 2).
Oligoclonal expansions were however extensively 
observed in NPC1-2 based on identical CDR3, and the 
largest expansion in NPC1 accounted for 2.4% of all IgG 
transcripts and in NPC2 for 7.8%. Our data also indicate 
that in deep sequencing of IgG transcripts in MM, the 
cut-off required to identify the tumor clone is likely to be 
higher (>7.8%).
Pattern of SHM in clonally related IGHV gene 
sequences in normal PCs
The largest oligoclonal expansions of IgG transcripts 
in NPC1-2 were evaluated, and subclonal variants 
related by identical CDR3 in each expansion aligned 
at the nucleotide level, using the top 10 most prevalent 
variant sequences (Figure 3). In 2 of 2 normal BM PC 
populations, oligoclonal expansions reveal marked ICV 
(Figure 3), comparable in mutational load and variation to 
that observed in MM1-4. Analysis of phylogenetic trees 
indicated comparable degrees of branching and therefore 
exposure to comparable rounds of SHM in evolution 
of clonally-related normal PCs and of clonally-related 
malignant PCs (Figure 4).
DISCUSSION
On-going SHM occurs in B-cells during extensive 
proliferation within the DZ of a GC, whereas in the LZ 
key selection events dictate B-cell fate [1, 4, 5]. Improved 
affinity for antigen by SHM allows preferential access 
to TFH cells in the LZ for extended stimuli, which appear 
to dictate either re-entry to the DZ or differentiation 
[7, 16]. The precise nature of signals and immunological 
synapses that determine fate as memory B-cell or PC 
in the GC however are as yet not fully defined, but are 
orchestrated by specific transcription factors. Of these, 
IRF4 is required for induction of AID and CSR and for 
derivation of PCs [17]. Specifically, graded expression of 
IRF4 regulates AID levels and induction of Blimp-1, an 
obligate requirement for terminal differentiation of PCs 
[18]. Interestingly, a ‘pre-PC’ stage has been described that 
delineates GC B-cell commitment to PC fate and precedes 
Blimp-1 expression and is able to undergo SHM, also 
expressing Flt3 and Embigin that are repressed by Pax5 
at an earlier stage [19]. Normal B-cells that undergo SHM 
but fail to improve fit for antigen undergo apoptosis by a 
default mechanism [2, 20, 21]. This check-point however 
may be by-passed by transformation, as suggested by GC 
B-cells that carry the t(14;18) translocation in follicular 
lymphoma [22].
The clonal nature of PCs derived from selection 
events in the GC can be gauged from IGHV gene analysis 
in data from the T-dependent response to a (4-hydroxy-
3-nitrophenyl) acetyl-protein conjugate antigen in murine 
B-cells, seeking to assess a role for affinity in antibody 
secreting cell (ASC) selection and migration to the BM 
[23]. These experiments clearly show clonal waves of 
isotype switched antigen specific ASCs migrating to the 
BM, displaying clonally-related VH186.2 gene sequences 
with marked ICV. These observations also indicate that 
clonal variants that are antigen-specific are selected in 
the GC to mature sequentially or synchronously to ASCs 
for homing to the BM, with late GC emigres displaying 
further evidence of accrual of SHM imprints in VH186.2 
sequences [23], consistent with re-entry to DZ of antigen-
selected B-cells.
Data from our analysis of IGHV genes in normal 
human PCs from the BM reflect these features of selection 
in antigen-specific murine ASCs [23]. We observed 
Oncotarget5www.impactjournals.com/oncotarget
oligoclonal expansions of normal PCs with marked ICV 
in each. Comparable observations were also reported 
in a study of normal BM PCs from a single donor by 
deep sequencing, with the largest IGHV3-7 derived 
clonal expansion providing evidence of ICV to a level 
comparable to that seen in our data on normal PCs [24]. 
These findings delineate that LLPCs in the BM comprise 
multiple variant subclones within oligoclonal expansions 
Figure 2: Monoclonal tumor-derived IGHV gene sequences dominate the compendium of IgG transcripts in MM 
as compared with oligoclonal expansions of IGHV gene sequences derived from non-tumor or normal plasma cells 
in the bone marrow. All IgG transcripts identified by deep sequencing were aligned with germline IGHV gene databases and CDR3 
identity used to group clonally related IGHV sequences in MM1-4, NPC1-2 and MM5. The frequency of each dominant clone in MM and 
oligoclonal expanions in normal plasma cells or non-tumor plasma cells are shown as a percentage of the total number of distinct IgG 
transcript reads per sample, visualized as a bar chart.
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to specific antigens, which persist over time at this site. 
Normal LLPCs in the BM are known to derive mainly 
from GC B-cells [11, 25].
In our earlier study of MGUS, IGHV gene analysis 
carried out by conventional cloning and sequencing 
revealed monoclonal tumor-derived sequences with 
Figure 3: Oligoclonal expansions identified in IGHV gene sequences derived from normal plasma cells in the bone 
marrow reveal marked intraclonal variation. IgG transcript profiles obtained by deep sequencing were aligned with germline 
IGHV genes and CDR3 identity used to identify oligoclonal expansions in normal human plasma cells. Only informative selected codons 
are shown, not entire IGHV genes. The largest oligoclonal expansion in each of NPC1 and NPC2 samples are shown, indicating % homology 
to donor germline gene, and the top 10 clonally-related transcripts are aligned at the nucleotide level to show sequence identity to the top 
read (by dots) or replacement nucleotides as shown in sequences. The data reveals a significant level of intraclonal variation in oligoclonal 
expansions of normal plasma cells in IGHV gene sequence mutations. Translation to deduced amino acid (aa) are also shown comparing 
germline with plasma cell IGHV gene sequence. For both NPC1 and NPC2 aligned sequence matches start at position 65.
Figure 4: Phylogenetic trees delineating hierarchical derivation of clonally related IGHV gene sequences in MM and 
in normal plasma cells in the bone marrow. Phylogenetic analysis of the 10 most prevalent clonal expansions linked by identical 
CDR3 motifs in MM and normal plasma cells were aligned using Clustal Omega and nearest neighbor joining trees plotted. Node numbers 
indicate read count for each sequence variant.
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marked ICV in 3 of 7 cases [13], to mirror characteristics 
of oligoclonal expansions of normal LLPCs in the BM. 
The IGHV gene data on MGUS suggested origins from 
a GC B-cell exposed to on-going SHM, and that has 
acquired a neoplastic genomic Event 1 to by-pass the 
default apoptotic fate dependent on antigen selection 
pressure [13, 14]. Such a cell of origin in MGUS would be 
predicted to be committed transcriptionally to a PC fate, 
but able to undergo further rounds of SHM in the DZ. The 
inference from the MGUS findings is that a comparable 
normal GC B-cell may exist, committed to terminal 
maturation but able to re-enter the DZ and undergo SHM, 
possibly a ‘pre-PC’ [19].
In contrast to MGUS, in our and others’ initial 
studies of MM-derived IGHV sequences, clonally 
homogeneous patterns of mutations were identified in 
individual MM cases, including in plateau phase of 
disease, but these data were based on analysis of limited 
numbers of clonally-related sequences [12]. The data 
suggested that neoplastic transformation occurs at a post-
follicular stage in MM, with the cell of origin no longer 
exposed to SHM [12]. However, in our IGHV gene study 
of 2 matched pairs of MGUS that evolve to MM, we 
identified that a single clone evolves in each case, and 
observed that in 1 of 2 matched pairs variant IGHV tumor 
sequences persisted to the MM stage of disease [14]. 
These appeared to be derived from ‘MGUS-like’ cells in 
the MM clone [14].
Based on these initial observations, we hypothesized 
that clonal tumor-derived variants may be more common 
in symptomatic MM presentation disease that could be 
traced in IGHV genes with the enhanced sensitivity of 
deep next generation sequencing. In the present study, 
we indeed readily identified clonal IGHV gene sequences 
with ICV in 4 of 4 typical MM cases, substantiating our 
hypothesis that this may be a frequent feature of MM 
disease. This finding has only emerged from massive 
parallel sequencing of IGHV genes, and was not readily 
apparent from lower depth of analysis by conventional 
methods. These data are consistent with the concept that 
the cell of origin in these MM arises during the GC, from 
a B-cell continually targeted by SHM but committed to 
terminal maturation to generate the ICV we observe in 
clonal IGHV sequences, and mirrors origins of MGUS 
(Figure 5). Given the seminal observations that most if 
not all MM originate directly from MGUS [26, 27], our 
data suggest that MM with ICV in IGHV gene mutations 
arises from the same GC cell of origin as in MGUS with 
ICV in IGHV gene mutations, with disease presenting first 
as MGUS.
Although in 3 of 4 MM cases, clonal outgrowth is 
dominated by a single sequence subclone, the remaining 
fractions of variant sub-clonal sequences with ICV are 
nevertheless highly significant. This emerges when we 
examine the known MM tumor mass. In IgG MM the 
total tumor cells per patient has been calculated as 
0.5 – 3.1 × 1012 based on data of in-vivo incorporation of 
125I into IgG [28]. To illustrate this, in MM2 50.7% of the 
clonal reads are sub-clonal variant sequences with ICV 
over and above the dominant sequence. Taking the lower 
estimate of tumor mass, 50.7% of 0.5 × 1012 equates to 
0.25 × 1012 transformed cells. Given that normal PCs only 
account for ~0.5–1.0% of mononucleated cells in the 
BM, and a total number of ~109 comprising the complete 
polyclonal pool [29], the ‘variant’ tumor mass in MM1-4 
can only be generated by proliferating transformed cells 
that persist.
Substantiating our observations, a recent study of 
a single MM case by massively parallel pyrosequencing 
also reported a dominant single clonal IGHV sequence 
with ICV [24]. Furthermore, in an initial report using 
the Lympho-SIGHT™ platform of high throughput 
sequencing of IGHV genes, in 401 MM cases, 71 (17.7%) 
showed evidence of clones related through SHM to the 
index clone at diagnosis [30]. Significantly, however, 
in the latter preliminary report [30], no conceptual 
framework was addressed to describe a possible pathway 
of clonal origins in MM in relation to the complexity 
of events in the GC, nor any association made with 
SHM patterns that we previously reported in MGUS 
[13]. Nevertheless, this initial report as an Abstract [30] 
appears to firmly substantiate our data that intraclonal 
variation in tumor-derived IGHV sequences occurs in 
MM. Additional high-throughput sequencing of IGHV 
genes in MM with the Lympho-SIGHT™ platform has 
also been reported directed at investigating minimal 
residual disease [15].
SHM levels in both MGUS and MM clonal IGHV 
genes are comparable in mutational load to normal LLPCs 
in the BM that largely derive from GC B-cells [11, 25], 
supporting the concept of GC origins of transformed PCs. 
MGUS cells retain expression of CD27 in most cases, 
although it is largely shed more frequently by aberrant 
MM PCs [31]. CD27 expression is acquired via GC 
trafficking [10].
With regard to a GC cell of origin that undergoes 
SHM and is committed to terminal maturation, previous 
investigations of IgD+ GC B-cells are noteworthy. In early 
studies, a subset of sIgM-IgD+CD38+ GC centroblasts 
were identified that have undergone class switch by 
Cμ–Cδ deletion, exhibit a marked λ light chain restriction 
and are supramutated in IGHV genes, but only differentiate 
to PCs in-vivo and do not circulate as memory B-cells [32]. 
Of high relevance, these IgD+ GC B-cells have also been 
proposed as the cell of origin in rare IgD+ MM disease, 
which reveal comparable genetic features of supramutated 
IGHV tumor-derived genes, a λ light chain bias and switch 
by Cμ deletion [32, 33].
Deletional CSR events occur in T-dependent antigen 
GC responses in B-cells [2, 4, 7]. Most MM are derived 
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from isotype switched cells, and in MM that switch to IgG 
on the functional allele, a single switch event occurs that is 
retained and can be tracked as a signature nucleotide motif 
in relapse disease [34]. This is an important observation, as 
it shows clonal origins in MM from a single switch event 
that correctly ligates CSR on the functional allele. Such 
a switched cell must then re-enter the DZ to be subjected 
to further SHM to generate the ICV we observe in IGHV 
gene sequences in MM cells (schematically represented 
in Figure 5). The non-functional allele however provides 
important clues that the stage of deletional CSR events 
associates with the impact of Event 1 in clonal origins of 
MM. Dysregulated CSR activity on this allele generates 
chromosomal translocations that map to the IgH 14q32 
locus in the main to SH switch sites, and has been widely 
recognized as an early pathogenetic event in MM [35, 36]. 
Aberrant deletional CSR events most likely occur in a 
background of genomic instability that may have resulted 
from Event 1 (Figure 5), possibly of an epigenetic 
nature, but these as yet remain unidentified. Event 1 is 
also predicted to allow escape from the normal antigen 
affinity associated GC check-point to by-pass apoptosis. 
AID activity underpins aberrant CSR events, as evident 
in B-cell tumors characterized by IgH locus translocations 
[37]. Several 14q32 translocations have recurrent partner 
chromosomes, restricted to subsets but none are universal 
to MM disease [35]. It is conceivable that in MM lacking 
aberrant 14q32 chromosomal translocations deletional 
CSR progresses without being dysregulated, and that the 
nature of Event 1 may differ. In MGUS, a comparable 
spectrum of 14q32 chromosomal translocations also 
occur in disease [35], and may also associate with timing 
of Event 1 in the GC-derived cell of origin.
It is generally accepted that secondary event(s) or 
lesion(s) underlie malignant transformation of MGUS to 
MM. At present, it is unclear from our data whether the 
variant sequences identified in monoclonal MM IGHV 
transcripts are derived from residual ‘MGUS-like’ cells 
or whether these cells persist as subclonal expansions 
because they have independently acquired separate 
secondary hit(s) as Events 2-N (Figure 5). These events 
may include mutations in key genes that when estimated 
as % of the tumor population emerge as subclonal 
events in different MM patients: KRAS (20–72%), NRAS 
(32–96%), BRAF (36–92%) or DIS3 genes (29–81%) 
[38]. Given that a long time-lag is usual in MGUS 
transforming to MM, subclonal neoplastic events could 
occur independently in cells with variant IGHV sequence. 
Data from mapping the genome in MM with aCGH and at 
the exome and whole-genome levels substantiate clonal 
Figure 5: A distinct pathway of clonal evolution in MGUS and MM originating from a germinal center B cell 
undergoing somatic hypermutation. Striking intraclonal variation (ICV) in patterns of tumor-derived IGHV gene sequence mutations 
in MM suggest a model in which a germinal center (GC) B cell that has undergone neoplastic Event 1, possibly at the stage of deletional 
class-switch recombination, re-enters the GC dark zone and is subjected to on-going somatic hypermutation (SHM). It is postulated that 
such a cell may be a ‘pre-PC’ committed to terminal maturation but able to undergo SHM, which exits the GC to home to the bone marrow 
to accumulate as MGUS. Subsequent sum of neoplastic Events 2-N in MGUS cells generate malignant MM, which retain the imprint of 
ICV resulting from the GC cell of origin being exposed to on-going SHM in tumor-derived IGHV genes.
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evolution, where SNP abnormalities or acquired somatic 
mutations in individual tumors are shared only by some 
cells not others in individual cases, and on-going subclonal 
competition appears to promote tumor survival and 
progression [38–42]. Events 2-N in progression may also 
include epigenetic genome modifications or dysregulation 
at the miRNome level and microenvironment dependent 
modulation of tumor cells. Many mutations identified 
in MM cells already exist at the MGUS stage of disease 
[43, 44], and while many acquired somatic mutations are 
common to disease subsets none are universal, further 
closely associating the molecular pathways of origins in 
MGUS and MM.
The GC emerges as a crucible in genesis of MGUS 
and MM via a distinctive pathway in which the cell of 
origin is targeted by on-going SHM. The question now is 
what the nature(s) of Event 1 or additional lesions might 
be in GC origins of MGUS and MM. This pathway may 
also lead to MM in which clonal IGHV sequences are 
homogeneous even by deep sequencing, by a ‘cloning out’ 
phenomenon or that in clonally homogeneous MM the cell 
of origin may arise later with SHM silenced as we had 
proposed earlier [13, 14]. Fully elucidating these pathways 
will crystalize origins of MM, and inform models of 
disease [45, 46].
MATERIALS AND METHODS
Patients and samples
Bone marrow samples of MM patients and normal 
donor (NPC1) were obtained for study with written 
informed consent in accordance with the Declaration of 
Helsinki and as approved by institutional ethics review 
committees. NPC1 was a donor undergoing orthopedic 
corrective surgery with no underlying disease. NPC2 cells 
were purchased from DV Biologics (Costa Mesa, CA, 
USA) as Bone Marrow Mononuclear Cells.
MM1-4 cases were previously untreated with 
symptomatic disease and CRAB features requiring active 
therapy (MM4 was plasma cell leukemia, with tumor 
cells purified from blood): MM1 IgGκ, MM2 IgGκ, 
MM3 IgGκ, and MM4 IgGλ. MM5 was an IgAκ tumor, 
previously treated and in 2nd relapse and used as a control 
to assess any bias in deep sequencing IgG transcripts. 
MM1-4 samples were at diagnosis prior to therapy.
PC purification
MM tumor cells were purified by automated CD138 
magnetic cell sorting (Miltenyi). CD19+CD38++CD138+ 
normal PCs were purified by cell sorting using a BD 
FACSAria or FACSVantage (BD Biosciences, Oxford, UK) 
with CD19-APC-eFluor780/-CyChrome (eBioscience, 
Hatfield, UK; BD Biosciences), CD38-FITC (BioLegend, 
London, UK) and CD138-BV510/-PE (BD Biosciences).
RNA
Total RNA was extracted from MM tumor cells and 
NPC using the Allprep or RNeasy kits (Qiagen, Crawley, 
UK) in accordance with the manufacturer’s protocol.
IGHV gene sequencing
Each RNA sample was separated into two and 
treated thereafter as two technical replicates.
cDNA was synthesized using SMARTscribe reverse 
transcriptase (Clontech Laboratories, Inc.) according 
to the manufacturer’s recommended protocol. Briefly, 
1 μL total RNA (1 to 145 ng) was added to 1 μL 20 μM 
3’ SMART CDS Primer IIA and 2.5 μL dH2O and the 
sample was incubated at 72°C for 3 minutes, followed 
by 42°C for 2 minutes. Samples were supplemented 
with 2 μL 1st strand buffer, 0.25 μL 20 mM DTT, 1 μL 
10 mM dNTPs, 1 μL SMARTer IIA oligonucleotide (5′ 
AAGCAGTGGTATCAACGCAGAGTACGCrGrGrG-3′), 
0.25 μL recombinant RNase inhibitor and 1 μL 
Smartscribe reverse transcriptase, followed by incubation 
at 42°C for 1 hour.
IGHV region amplicons were generated from 
cDNA by PCR using individual pools of forward primers 
within framework region 1 (FR1) that were designed to 
amplify all known IGHV region alleles, and a reverse 
primer within the IgG constant region. Both primer sets 
incorporated Illumina P5 or P7 adaptor sequences at their 
5’ ends to facilitate sequencing. We used Phusion Flash 
High-fidelity Taq polymerase (Life Technologies, UK) for 
PCR, which has a reported error rate of 4.4 × 10−7/bp/PCR 
cycle [47].
Amplicons were purified using an eGel Size-Select 
electrophoresis system (Life Technologies, UK) to select 
products within the anticipated size range of approximately 
400–450 bp. 250 bp paired-end sequencing was performed 
on an Illumina MiSeq sequencer using a pool of read1 
sequencing primers matching the pool of FR1 primers 
but omitting the Illumina adaptor sequence, an indexing 
primer to provide indexing information and a read2 primer 
matching the IgG constant region amplification primer that 
also lacked the Illumina adaptor sequence.
Sequence quality control, paired end joining 
and filtering
Sequence read-pairs were combined using the Flash 
utility [48]. Sequence pairs which did not meet the quality 
criteria or which were shorter than 300 bp once combined 
were excluded from further analysis.
Sequence analysis
All assembled variable region nucleotide sequences 
were processed using the VDJfasta utility [49]. VDJFasta 
uses a Hidden Markov Model to statistically analyze 
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sequences upstream and downstream of putative 
CDR3s and outputs V, D and J germline sequences, 
CDR3 sequences and translated protein sequences 
derived from each read. To increase processing speed, 
sequence processing using this utility was parallelized 
using custom Perl and Python scripts and run on the 
parallel computing facility provided by the University 
of Edinburgh Compute and Data Facility (ECDF, http://
www.ecdf.ed.ac.uk/).
Neighbor-joining trees
For each donor, the 10 most prevalent variable 
region sequences derived from a clonal expansion with 
identical CDR3 were aligned using Clustal Omega, 
phylogenetic trees were calculated using the Neighbor-
Joining algorithm [50] and trees rendered using FigTree 
v1.4 (http://tree.bio.ed.ac.uk/software/figtree/).
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